BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24740828)

  • 1. Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.
    Kishi Y; Shimada K; Nara S; Esaki M; Hiraoka N; Kosuge T
    Ann Surg Oncol; 2014 Sep; 21(9):2882-8. PubMed ID: 24740828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
    Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
    World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
    Sallinen V; Haglund C; Seppänen H
    Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic neuroendocrine tumor: A multivariate analysis of factors influencing survival.
    Birnbaum DJ; Turrini O; Ewald J; Barbier L; Autret A; Hardwigsen J; Brunet C; Moutardier V; Le Treut YP; Delpero JR
    Eur J Surg Oncol; 2014 Nov; 40(11):1564-71. PubMed ID: 25086992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
    Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
    Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the 2-cm size cutoff relevant for small nonfunctioning pancreatic neuroendocrine tumors: A French multicenter study.
    Regenet N; Carrere N; Boulanger G; de Calan L; Humeau M; Arnault V; Kraimps JL; Mathonnet M; Pessaux P; Donatini G; Venara A; Christou N; Bachelier P; Hamy A; Mirallié E
    Surgery; 2016 Mar; 159(3):901-7. PubMed ID: 26590096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical strategies for non-functioning pancreatic neuroendocrine tumours.
    Kim MJ; Choi DW; Choi SH; Heo JS; Park HJ; Choi KK; Jang KT; Sung JY
    Br J Surg; 2012 Nov; 99(11):1562-8. PubMed ID: 23027073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.
    Dong DH; Zhang XF; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
    J Surg Oncol; 2019 Dec; 120(7):1071-1079. PubMed ID: 31571225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary treatment strategy for advanced pancreatic neuroendocrine tumors- a single center experience.
    Tsuchikawa T; Hirano S; Tanaka E; Kato K; Matsumoto J; Sichinohe T
    Hepatogastroenterology; 2012; 59(120):2623-6. PubMed ID: 22497945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Prognosis of Resected Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease Is Favorable and Not Influenced by Small Tumors Left in Place.
    de Mestier L; Gaujoux S; Cros J; Hentic O; Vullierme MP; Couvelard A; Cadiot G; Sauvanet A; Ruszniewski P; Richard S; Hammel P
    Ann Surg; 2015 Aug; 262(2):384-8. PubMed ID: 25185468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management.
    Lopez-Aguiar AG; Ethun CG; Zaidi MY; Rocha FG; Poultsides GA; Dillhoff M; Fields RC; Idrees K; Cho CS; Abbott DE; Cardona K; Maithel SK
    Surgery; 2019 Jul; 166(1):15-21. PubMed ID: 31072670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.
    Cherenfant J; Stocker SJ; Gage MK; Du H; Thurow TA; Odeleye M; Schimpke SW; Kaul KL; Hall CR; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA; Talamonti MS
    Surgery; 2013 Oct; 154(4):785-91; discussion 791-3. PubMed ID: 24074416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggressive pancreatic resection for primary pancreatic neuroendocrine tumor: is it justifiable?
    Teh SH; Deveney C; Sheppard BC
    Am J Surg; 2007 May; 193(5):610-3; discussion 613. PubMed ID: 17434366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection.
    Partelli S; Crippa S; Barugola G; Tamburrino D; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Ann Surg Oncol; 2011 Dec; 18(13):3608-14. PubMed ID: 21584836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs).
    Partelli S; Gaujoux S; Boninsegna L; Cherif R; Crippa S; Couvelard A; Scarpa A; Ruszniewski P; Sauvanet A; Falconi M
    JAMA Surg; 2013 Oct; 148(10):932-9. PubMed ID: 23986355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.